BRPI0904960A2 - Método para tratar um mamífero que sofre de dor - Google Patents

Método para tratar um mamífero que sofre de dor

Info

Publication number
BRPI0904960A2
BRPI0904960A2 BRPI0904960-6A BRPI0904960A BRPI0904960A2 BR PI0904960 A2 BRPI0904960 A2 BR PI0904960A2 BR PI0904960 A BRPI0904960 A BR PI0904960A BR PI0904960 A2 BRPI0904960 A2 BR PI0904960A2
Authority
BR
Brazil
Prior art keywords
painful
mammal
treating
painful mammal
Prior art date
Application number
BRPI0904960-6A
Other languages
English (en)
Inventor
John Myers Zanella
Vanja Margareta King
Christopher M Hobot
Keit R Hildebrand
Original Assignee
Warsaw Orthopedic Inc
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warsaw Orthopedic Inc, Medtronic Inc filed Critical Warsaw Orthopedic Inc
Publication of BRPI0904960A2 publication Critical patent/BRPI0904960A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0904960-6A 2008-04-18 2009-04-17 Método para tratar um mamífero que sofre de dor BRPI0904960A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4620108P 2008-04-18 2008-04-18
US15381709P 2009-02-19 2009-02-19
US12/397,869 US20090264489A1 (en) 2008-04-18 2009-03-04 Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
PCT/US2009/040961 WO2009129464A2 (en) 2008-04-18 2009-04-17 Method for treating acute pain with a formulated drug depot in combination with a liquid formulation

Publications (1)

Publication Number Publication Date
BRPI0904960A2 true BRPI0904960A2 (pt) 2015-06-30

Family

ID=41199765

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0904960-6A BRPI0904960A2 (pt) 2008-04-18 2009-04-17 Método para tratar um mamífero que sofre de dor

Country Status (8)

Country Link
US (1) US20090264489A1 (pt)
EP (1) EP2288353A2 (pt)
JP (1) JP2011518183A (pt)
CN (1) CN101820876A (pt)
AU (1) AU2009236119A1 (pt)
BR (1) BRPI0904960A2 (pt)
CA (1) CA2700196A1 (pt)
WO (1) WO2009129464A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005053819A1 (de) * 2005-11-11 2007-05-16 Khd Humboldt Wedag Gmbh Drehofenbrenner
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US20110097375A1 (en) * 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
EP2345732A1 (en) * 2010-01-19 2011-07-20 Universite Paris Descartes Methods for intracellular delivery of nucleic acids
US8221428B2 (en) 2010-01-26 2012-07-17 Warsaw Orthopedic, Inc. Sacro-iliac joint implant system, method and instrument
US20110184520A1 (en) * 2010-01-27 2011-07-28 Warsaw Orthopedic, Inc. Sacro-iliac joint implant, method and apparatus
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US8945224B2 (en) * 2010-03-18 2015-02-03 Warsaw, Orthopedic, Inc. Sacro-iliac implant system, method and apparatus
US20110238181A1 (en) * 2010-03-29 2011-09-29 Warsaw Orthopedic, Inc., A Indiana Corporation Sacro-iliac joint implant system and method
US9039765B2 (en) 2011-01-21 2015-05-26 Warsaw Orhtopedic, Inc. Implant system and method for stabilization of a sacro-iliac joint
JP6224579B2 (ja) * 2011-04-11 2017-11-01 インデュース バイオロジクス インコーポレイテッドＩｎｄｕｃｅ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 増殖因子の多相放出を行うためのシステムおよび方法
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
CN107106482A (zh) * 2014-11-06 2017-08-29 罗伯特·E·诺德奎斯特 用于减轻疼痛和炎症、治疗勃起机能障碍和治疗痤疮的组合物和方法
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
KR101852718B1 (ko) * 2017-04-04 2018-05-18 주식회사 제네웰 외과수술 후 절개부위 통증 감소를 위한 키트
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
CN116650732A (zh) 2018-01-08 2023-08-29 铸造疗法股份有限公司 经由治疗剂的控制递送用于治疗腔内癌症的装置、系统和方法
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
WO2020047013A1 (en) 2018-08-28 2020-03-05 Foundry Therapeutics, Inc. Polymer implants
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020660A (en) * 1959-11-30 1962-02-13 Scherotto John Collapsible imitation tree
US3202660A (en) * 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
US4765974A (en) * 1985-12-24 1988-08-23 Nitto Electric Industrial Co., Ltd. Preparation for percutaneous administration
US5175052A (en) * 1988-05-11 1992-12-29 Nitto Denko Corporation Adhesive tape preparation of clonidine
US5447947A (en) * 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
DE69603577T2 (de) * 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US7179255B2 (en) * 1995-06-07 2007-02-20 Arthrocare Corporation Methods for targeted electrosurgery on contained herniated discs
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US5801188A (en) * 1997-01-08 1998-09-01 Medtronic Inc. Clonidine therapy enhancement
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US5942530A (en) * 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6179862B1 (en) * 1998-08-14 2001-01-30 Incept Llc Methods and apparatus for in situ formation of hydrogels
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
US6147102A (en) * 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE50009346D1 (de) * 1999-11-29 2005-03-03 Novosis Ag Transdermalsystem zur Abgabe von Clonidin
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6417184B1 (en) * 2000-09-19 2002-07-09 David M. Ockert Triple drug therapy for the treatment and prevention of acute or chronic pain
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US6631055B2 (en) * 2001-06-08 2003-10-07 International Business Machines Corporation Tunnel valve flux guide structure formed by oxidation of pinned layer
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
MXPA01011542A (es) * 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
ES2601143T3 (es) * 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040166088A1 (en) * 2003-01-15 2004-08-26 Shalaby Shalaby W. Polymeric precursors of non-absorbable, in situ-forming hydrogels and applications thereof
US20040208917A1 (en) * 2003-04-16 2004-10-21 Wilfried Fischer Transdermal systems for the release of clonidine
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) * 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2540895C (en) * 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
WO2005065079A2 (en) * 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
WO2005074913A2 (en) * 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
US7294138B2 (en) * 2004-06-28 2007-11-13 Shippert Ronald D Nose pack method and apparatus
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
AU2005306309A1 (en) * 2004-11-17 2006-05-26 Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Steroid formulation and methods of treatment using same
AU2005309586A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US7611494B2 (en) * 2005-02-08 2009-11-03 Confluent Surgical, Inc. Spray for fluent materials
JP2006306739A (ja) * 2005-04-26 2006-11-09 Japan Science & Technology Agency 神経因性疼痛治療剤
US8551961B2 (en) * 2005-05-25 2013-10-08 Massachusetts Institute Of Technology Localized delivery of cardiac inotropic agents
US9259267B2 (en) * 2005-09-06 2016-02-16 W.L. Gore & Associates, Inc. Devices and methods for treating cardiac tissue
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7741273B2 (en) * 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US8974542B2 (en) * 2006-06-27 2015-03-10 University of Pittsburgh—of the Commonwealth System of Higher Education Biodegradable elastomeric patch for treating cardiac or cardiovascular conditions
CA2692430A1 (en) * 2006-07-07 2008-01-10 Bioassets Development Corporation Methods for preventing, postponing or improving the outcome of spinal device and fusion procedures
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
US7671014B2 (en) * 2006-08-14 2010-03-02 Warsaw Orthopedic, Inc. Flowable carrier matrix and methods for delivering to a patient
US20080091207A1 (en) * 2006-10-13 2008-04-17 Csaba Truckai Bone treatment systems and methods
US20080152709A1 (en) * 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
WO2009100441A2 (en) * 2008-02-08 2009-08-13 Impax Laboratories, Inc. Depot formulations

Also Published As

Publication number Publication date
WO2009129464A2 (en) 2009-10-22
JP2011518183A (ja) 2011-06-23
WO2009129464A3 (en) 2010-01-07
EP2288353A4 (en) 2011-03-02
AU2009236119A1 (en) 2009-10-22
EP2288353A2 (en) 2011-03-02
WO2009129464A4 (en) 2010-03-18
US20090264489A1 (en) 2009-10-22
CN101820876A (zh) 2010-09-01
CA2700196A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
BRPI0904960A2 (pt) Método para tratar um mamífero que sofre de dor
BRPI0916184A2 (pt) método para a formação de um equipamento de iluminação e equipamento de iluminação
BRPI0911885A2 (pt) processo para a redução de atrito
BRPI0906906A2 (pt) Método para preparar um composto e composto
BRPI0907556A2 (pt) Dispositivo a laser para tratamento da queda de cabelo
BRPI0919615A2 (pt) método e dispositivo para operação de um processo de redução de fundição
BRPI0913156A2 (pt) método e aparelho para acesso a link seguro direto
BRPI0914906A2 (pt) aparelho e método para a geração de névoa
BRPI0721502A2 (pt) Método para tratamento de uma formação fraturada
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI0908192A2 (pt) Dispositivo funcional, e, método para produzir um dispositivo funcional
BRPI0911545A2 (pt) dispositvo para a produção de um componente assim como método e componente
BRPI0918349A2 (pt) Processo para preparar dióxido de divinilareno
BRPI0920920A2 (pt) processo para dessulfuração
BRPI1013561A2 (pt) Processo para a preparação de alogliptina
BRPI1010628A2 (pt) "dispositivo e método para produção de um componente compósito"
BRPI0916126A2 (pt) Dispositivo de desafio de processo e método para determinar a eficácia de um processo de esterilização
BRPI0810169A2 (pt) Processo e máquina para abaixamento de um trilho
BRPI1008964A2 (pt) Dispositivo para um processo fotoquímico
BRPI1012025A2 (pt) componente estrutural e método para produção de um componente estrutural.
BRPI0914680A2 (pt) método para produção de dispositivos de distribuição
BRPI0912275A2 (pt) sistema de compressor e processo para operar um sistema de compressor
BRPI0811844A2 (pt) Composto, e, método para tratar um paciente
BRPI0918801A2 (pt) método para alisamento de fibras queratinosas
BRPI0916818A2 (pt) Método para tratamento de dentes sensíveis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.